Aimfinity Investment Corp I Enters Into $60M SPAC Merger Agreement With Taiwanese Smart Medical Device Developer Docter Inc
Aimfinity Investment Corp I Enters Into $60M SPAC Merger Agreement With Taiwanese Smart Medical Device Developer Docter Inc
Aimfinity Investment Corp. I ("Aimfinity") (NASDAQ:AIMAU), a Cayman Islands incorporated special purpose acquisition company listed on the Nasdaq Global Market, and Docter Inc. ("Docter"), a Taiwanese
在納斯達克全球市場上市的開曼群島註冊特殊目的收購公司Aimfinity Investment Corp. I（“Aimfinity”）（納斯達克股票代碼：AIMAU）和臺灣Docter Inc.（“Docter”）（“Docter”）
Aimfinity Investment Corp. I ("Aimfinity") (NASDAQ:AIMAU), a Cayman Islands incorporated special purpose acquisition company listed on the Nasdaq Global Market, and Docter Inc. ("Docter"), a Taiwanese non-invasive blood glucose watch developer, today announced that they have entered a definitive merger agreement (the "Merger Agreement") pursuant to which a newly established subsidiary of Aimfinity will become a publicly listed company combining Aimfinity and Docter (the "Combined Company") upon the closing of the transaction contemplated therein (the "Proposed Transaction"). Upon closing, the Combined Company expects to list its ordinary shares on Nasdaq.
在納斯達克全球市場上市的開曼群島註冊的特殊目的收購公司Aimfinity Investment Corp. I（“Aimfinity”）（納斯達克股票代碼：AIMAU）和臺灣非侵入性血糖手錶開發商Docter Inc.（“Docter”）今天宣佈，他們已簽訂最終合併協議（“合併協議”），根據該協議，Aimfinity的一家新成立的子公司將成爲合併Aimfinity的上市公司 Ity and Docter（“合併後的公司”）在其中設想的交易完成時（“擬議”交易”)。收盤後，合併後的公司預計將在納斯達克上市。
As provided in the Merger Agreement, the merger consideration is $60,000,000, payable by newly-issued shares of the Combined Company valued at $10.00 per share. Additional earnout shares may be issuable to Docter stockholders after closing, upon achievement of certain sales targets in 2024 and 2025.
根據合併協議的規定，合併對價爲6,000萬美元，由合併後公司新發行的股票支付，每股價值10.00美元。在2024年和2025年實現某些銷售目標後，可能會在收盤後向Docter股東發行額外的收益股份。
Following the closing, assuming no redemption by existing public shareholders of Aimfinity, the Aimfinity shareholders will have approximately 51.92% equity interest in the Combined Company and the Docter Stockholders will have approximately 48.08% equity interest in the Combined Company. If, however, there is a maximum redemptions of existing public shareholders of Aimfinity resulting in remaining balance of trust account of $5,000,000, the Aimfinity shareholders will have approximately 29.45% equity interest in the Combined Company and the Docter stockholders will have approximately 70.55% equity interest in the Combined Company.
收盤後，假設現有公衆股東沒有贖回Aimfinity，則Aimfinity股東將擁有合併後公司約51.92％的股權，而Docter股東將擁有合併後公司約48.08％的股權。但是，如果Aimfinity現有公衆股東的最大贖回額爲500萬美元，則Aimfinity股東將擁有合併後公司約29.45％的股權，而Docter股東將擁有合併後公司約70.55％的股權。
譯文內容由第三人軟體翻譯。